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In conclusion, TS in recipients of TBI is associated with signif-
icantly lower risk of opportunistic infections without any deleteri-
ous effect on hematopoietic recovery in recipients of AD-HSCT.
While these results indicate that TS reduces the infection rate and
potentially improves survival in patients with FA, they also suggests
that TS should be considered for other high risk populations (e.g.
adults) and in those with other non malignant disorders. While it
appears that immune reconstitution is improved based on the
reduced incidence of opportunistic infections, correlative labora-
tory assessments (TREC, CD4 recovery) are currently being per-
formed.
Impact of TS on HSCT Outcomes
Preparative
Therapy
Probability
of
Neutrophil
Engraftment
(95% CI)
Probability
of Survival
at 1 Year
(95% CI)
Total #
Infections
#Bacterial
Infections
#Viral
Infections
#Fungal
Infections
TBI with
TS
(n16
patients) 94(82-100) 67(23-91) 9 4 3 2
TBI
Without
TS
(n43
patients) 97(92-100) 53(38-68) 126 68 37 21
P value NS NS <.01 <.01 <.01 <.01
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CD4CD25 REGULATORY T CELLS ENHANCE IMMUNE RECONSTI-
TUTION FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION BY PROTECTING THYMIC AND LYMPHOID COMPART-
MENTS FROM GRAFT-VERSUS-HOST DISEASE DAMAGE WITHOUT
IMPACTING T CELL REPERTOIRE DEVELOPMENT
Nguyen, V.H.1, Chang, D.1, Shashidhar, S.1, Bachmann, M.1,
Contag, C.H.1, Brown, J.M.Y.1, Negrin, R.S.1 1Stanford University
School of Medicine, Stanford, CA.
We previously showed that Treg improved the quantitative
and functional lymphoid reconstitution in a murine model of
bone marrow transplantation. We hypothesize that Treg pre-
vent thymic and lymphoid damage from graft-versus-host dis-
ease (GvHD), leading to enhanced lymphoid reconstitution.
Lethally-irradiated adult thymectomized Balb/c (H2d) recipi-
ents received FVB (H2q) T cell depleted bone marrow (TCD-
BM) cells and CD4/CD8 cells (Tcon), the latter to induce
GvHD, with or without donor Treg. At day 30, when all groups
had reached full donor chimerism, transplant recipients were
challenged with murine CMV (5105 pfu/mouse). Day 90 sur-
vival for thymectomized groups with TCD-BM alone, with
Tcon, or with TconTreg was 78%, 0%, and 45%, respec-
tively, compared to 100%, 0%, and 86% survival in their re-
spective euthymic infected counterparts (p0.05 for thymecto-
mized vs euthymic Treg groups). Elispot showed CMV speciﬁc
donor responses in infected groups. Viral titers in the liver and
kidney 2 weeks after infection was lower in Treg recipients
compared to animals that received Tcon alone. Thymectomized
animals had higher viral titers compared to euthymic controls.
Uninfected thymectomized controls in the respective groups
separate the effect of CMV infection from GvHD on survival.
Treg recipients, infected or uninfected, had no clinical GvHD
compared to animals that received Tcon alone. In euthymic
recipients, gross and histologic examination conﬁrmed the gen-
eral preservation of thymic integrity and architecture in Treg
recipients compared with smaller involuted thymuses partially
replaced by adipose tissue in animals that received Tcon alone.
V-beta TCR screening with FACS showed a polyclonal TCR
repertoire in animals with or without Treg. Spectratyping 30
days post-transplantation showed that Treg had no signiﬁcant
impact on the TCR repertoire diversity in animals which re-
ceived Tcon. Survival of a subset of infected thymectomized
animals that received Treg lead to the evaluation of the impact
of Treg on secondary lymphoid organs following HCT. Animals
without Treg had signiﬁcant splenic and lymph node ﬁbrosis
and hypoplasia with a reduction in T cell numbers due to
GvHD. Our ﬁndings indicate that Treg indirectly enhance
immune reconstitution by protecting the thymic and secondary
lymphoid compartments from GvHD damage, allowing the
generation and peripheral expansion of lymphoid cells without
impacting the diversity of T cell repertoire.
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TRANSPLANT CONDITIONS DETERMINE THE CONTRIBUTION OF HOMEO-
STATICALLY EXPANDED DONOR CD8 CELLS TO HOST LYMPHOID RECON-
STITUTION FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
Roskos, M.1, Levy, R.B.1 1University of Miami, Miami, FL.
Patients undergoing hematopoietic cell transplantation (HCT) typ-
ically experience a period of immune deﬁciency commensurate with
levels of pre-transplant conditioning. Accordingly, developing ap-
proaches to facilitate the reconstitution of the host T cell compart-
ment and restore host immune function post-HCT is an important
clinical challenge. The capacity of T cells to expand under conditions
of lymphopenia is well recognized. To determine the contribution of
homeostatically expanded donor memory CD8 cells (TM) on the
reconstitution of the host CD8 compartment post-HCT, a homoge-
neous TCR-transgenic (tg) TM population was monitored following
transplantation with T cell-depleted C57BL/6 bone marrow into
9.0Gy-conditioned syngeneic recipients. Homeostatic expansion was
assessed by CD8/V5/V2 numbers in recipient spleens begin-
ning 3 days post-HCT. Infused TM expanded for 2 wks then reached
a steady-state splenic number (1.5x1) that was maintained 7
months post-transplant. Similar kinetics and expansion were observed
with a non-tg TM population. To determine how transplant param-
eters affect OT.I homeostatic expansion, reduced intensity condition-
ing, delayed infusion, and varying TM doses were examined. OT.I
TM transplanted after 4.5Gy TBI v 9.0Gy, underwent a shorter
period of expansion (1 v 2 wks) and resulted in lower overall homeo-
static cell numbers (3x2). OT.I TM infused into 9.0Gy-condtioned
recipients a week post-transplant displayed similar kinetics and
reached the same homeostatic number as OT.I cells infused at the
time of transplant. However, when the infusion was delayed for 3 wks,
there was marked reduction in expansion and lower homeostatic
numbers (6x2). Transplantation of 0.1106 OT.I TM v 1.5106
TM, after 9.0Gy, TBI resulted in a shorter period of expansion (1 v 2
wks) and lower set-point (4x2). Interestingly, transplantation of
10106 TM resulted in a rapid expansion the ﬁrst week and steep
contraction the second week followed by a rebound expansion and
contraction. Notably, the ultimate set-point was greater than that
achieved with 1.5106 TM (1.5x1). In total, these results demon-
strate the period of expansion and ultimate homeostataic numbers
depend on the level of conditioning, timing of infusion, and number
of TM transplanted. We conclude these parameters are important
when engineering new strategies designed to enhance immune func-
tion post-transplant, including both immediate anti-tumor immunity
and long-term anti-viral protection.
49
HAPLOTYPE MISMATCHED MYELOABLATIVE STEM CELL TRANSPLAN-
TATION: PHASE I CLINICAL TRIAL OF DONOR LYMPHOCYTE INFUSION
DEPLETED OF ALLOREACTIVE T CELLS TO LIMIT INFECTIONS AND
MALIGNANT RELAPSE WITHOUT CAUSING GVHD
Roy, D.C.1, Cohen, S.1, Busque, L.1, Fish, D.1, Kiss, T.1, Lachance, S.1,
Sauvageau, G.1, Caudrelier, P.2, Roy, J.1 1Hopital Maisonneuve-Rose-
mont, Montreal, QC, Canada; 2Celmed BioSciences, Montreal, QC,
Canada.
Patients with very high risk hematologic malignancies who cannot
ﬁnd an HLA-matched related or unrelated donor can beneﬁt from
haplo-mismatched transplantation. The latter is, however, compli-
cated by frequent and severe infectious complications and disease
relapse due to delayed immune reconstitution. We have previously
reported that photodynamic therapy (PDT) could selectively deplete
donor alloreactive populations while preserving lymphocytes for im-
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mune responses. We present results of an ongoing Phase I clinical
trial of haplo-mismatched allogeneic stem cell transplant (SCT) sup-
plemented with donor lymphocyte infusions (DLIs) PDT depleted of
host-reactive T cells. Nine high-risk patients with hematologic ma-
lignancies (5 AML relapsed or refractory, 2 MDS, 1 NHL, 1 refrac-
tory CLL) entered the trial, 7 (4 M, 3 F) are evaluable for acute
GVHD and immune reconstitution. Donor mononuclear cells
(MNCs) were incubated with recipient MNCs for 4 days, exposed to
TH9402 PDT, stored frozen, and administered on day 30	3 after
transplant at 3 graded DLI dose levels: 1104 (1pt), 5104 (3pts), and
1.3 105 (3pts) CD3 cells/kg. Anti-host cytotoxic T lymphocyte
precursors (CTLp) were depleted from DLIs by approximately 1.5
logs, and ﬂow cytometry showed greater than 90% elimination of
activated T cells (CD4CD25 and CD8CD25) by TH9402
PDT. Median age at SCT was 57 years (range: 40-58). The myeloa-
blative regimen consisted of TBI (1200 cGy), thiotepa (5 mg/kg) and
ﬂudarabine (40 mg/m2/day for 5 days) followed by infusion of CD3
depleted HSC grafts. No GVHD prophylaxis was administered.
Evaluable patients showed durable trilineage hematologic engraft-
ment and achieved complete donor chimerism. No patient developed
acute GVHD (grade II-IV), while 3 patients developed signs of
chronic GVHD. Two patients died: one (cohort 1) of a post-trans-
plant lymphoproliferative disease, and one (cohort 2), of relapsed
AML. No other patient relapsed. Two pts recovered greater than
0.3109 CD3 and CD4 cells/L at 2 and 5 months post-DLI, and
4 pts had 0.2109 CD3 cells/L at 6 mo post-DLI. Although 4
patients developed infectious complications (HSV, CMV, Nocardia,
Aspergillus), all resolved rapidly with appropriate therapy. The overall
disease-free-survival and survival are 57% at 1 year (median follow-up:
9.4 mo). Our results indicate that the post-transplant infusion of a
PDT treated DLI is feasible, does not induce acute GVHD, and may
accelerate T cell reconstitution.
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ENHANCED DEPLETION OF ALLOREACTIVE T CELLS USING COMBINED
CD25/71 IMMUNOMAGNETIC SELECTION
Samarasinghe, S.1, Karlsson, H.1, Nawroly, N.2, Openshaw, P.2, Veys, P.3,
Amrolia, P.1,3 1Institute of Child Health, London, United Kingdom; 2St.
Mary’s Hospital, Imperial College, London, United Kingdom; 3Great
Ormond Street Hospital for Children, London, United Kingdom.
Immunotherapy with allodepleted donor T-cells generated using
a CD25 immunotoxin improves immune reconstitution after
haplo-SCT, but leukaemic relapse remains a problem. To develop
a rational approach to reﬁning allodepletion, we characterised the
phenotype of proliferating alloreactive T cells ﬂow cytometrically.
CFSE-labelled T cells were co-cultured with HLA-mismatched
dendritic cells and serial FACS analyses performed to determine
expression of CD25, CD69, CD71, HLA-DR, OX40, ICOS,
CD95, CD45RA, CCR7, IFN, TNF, and IL-2. By staining each
sample with CD3, CFSE and CD25 we were able to determine the
phenotype of proliferating CD25 negative alloreactive T cells. In 5
donors, after a 3 day culture, CD25 was expressed in a mean of 83
% (67-89 %) of the proliferating (CFSE-dim) alloreactive T cells,
conﬁrming CD25 as an excellent target for allodepletion. 70 %
(39-81 %) of the proliferating alloreactive CD25 -ve population
expressed CD71, and 62 % (50-74 %) expressed CD45RA, iden-
tifying these two molecules, as markers of alloreactive T cells that
would be retained after CD25 based allodepletion. We then com-
pared residual alloreactivity after CD25 vs CD25/71 vs CD25/
45RA based allodepletion using negative selection with immuno-
magnetic beads in 5 HLA-mismatched donors-recipient pairs.
Primary MLRs showed a mean residual proliferation to host of
0.58 % (0-2.7 %) after CD25 depletion, 1.73 % (0– 7.6 %) after
CD25/45RA depletion and 0.04 % (0-0.2 %) for CD25/71 deple-
tion. IFN- ELISPOT analyses demonstrated that when recul-
tured with original stimulator, CD25 depletion led to a mean 88 %
reduction in IFN SFC compared to unmanipulated sensitized
PBMCs and this was enhanced by CD25/71 (95 %) or CD25/
45RA depletion (93 %) with third party responses maintained for
all 3 arms. In secondary MLRs, the mean residual proliferations to
the original stimulator was: CD25 allodepletion 0.71 % (0-1.14
%), CD25/CD71 0.01 %, (0-0.04 %) (CD25 vs CD25/71 p0.06)
and for CD25/CD45RA 14.85 % ( 0-33.09 %)(CD25 vs CD25/
45RA p0.028). Studies demonstrating preservation of antiviral
responses after CD25/71 depletion will be presented. We conclude
that CD25/71 allodepletion will selectively delete  90% of the
proliferating alloreactive T cells and enhances the depletion of
alloreactivity compared with CD25-based methods. This strategy
may facilitate immunotherapy with larger doses of allodepleted
donor T-cells after haplo-SCT, enhancing graft versus leukaemia
and antiviral effects.
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ANDROGEN WITHDRAWAL MODULATES THYMOPOIESIS BY INDUCING
THYMIC EPITHELIAL CELL PROLIFERATION AND ENHANCING THYMO-
CYTE DEVELOPMENT PRIOR TO INCREASING PRECURSOR IMMIGRA-
TION
Williams, K.M.1, Chu, Y.-W.1, Tayler, E.1, Gress, R.E.1 1Experimen-
tal Transplantation and Immunology Branch/NCI/NIH, Bethesda, MD.
Impaired thymopoiesis contributes to immune deﬁciency in ag-
ing, AIDS, and following allogeneic bone marrow transplantation.
Little is known of the mechanisms of thymic regulation. We show
that castration of male mice resulted in increased thymic size,
thymocyte number, intrathymic T cell receptor excision circles,
and the number of early thymic progenitors (ETP: Lin- CKIT hi
CD44 hi) as early as eight days post-castration. These observations
suggested a mechanism of enhanced thymopoieis that occurs
through increased immigration of thymocyte precursors presum-
ably due to increased circulating progenitors. However, the earliest
T cell progenitor population in the bone marrow (LSK: Lin-, c-kit
hi, Sca-1, IL7Ra-) was not increased in castrated mice. In addi-
tion, statistically signiﬁcant increases in thymocyte number and
early thymus subsets occurred on day 5, prior to the increase in
thymic ETPs (day 8). Five days post-castration, there was a statis-
tically signiﬁcant doubling of double negative (DN) thymocytes,
with the greatest increases in the DN3 and DN4 populations.
Double positive (DP) thymocytes (CD4CD8) were signiﬁ-
cantly increased as well. Furthermore, there was evidence of sig-
niﬁcantly increased proliferation of DN3 and increased transit into
DP thymocytes determined by bromodeoxyuridine (BRDU) incor-
poration reﬂected in DN3 and DP thymocytes at this time point.
These data suggest that intrathymic maturation of primitive thy-
mocytes is important early in the mechanism of enhanced thymo-
poiesis following androgen withdrawal. Preliminary data also dem-
onstrate a concomitant increase in the percentage of BRDU 
thymic epithelial cells (TEC) at day5, implicating stromal prolif-
eration in thymic expansion. Immunohistochemistry analyses using
laser scanning cytometery suggest an increase in both cortical and
medullary TEC subsets following castration. Finally, preliminary
adoptive transfer studies with congenic LSK suggest enhanced
uptake of ETP occur after these intrathymic changes. These data
suggest that androgen withdrawal leads to proliferation of thymic
epithelial cell subsets with enhanced maturation of early thymo-
cytes, followed by increased ETP entry into the thymus. These
studies have implications for enhanced thymopoiesis following
marrow transplant and identify two points of thymic regulation: 1)
TEC proliferation and 2) ETP entry into the thymus.
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LATE EFFECTS IN SURVIVORS OF ACUTE LEUKEMIA TREATED WITH
HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A REPORT FROM
THE BONE MARROW TRANSPLANT SURVIVOR STUDY (BMT-SS)
Baker, K.S.1, Ness, K.1, Weisdorf, D.1, Francisco, L.2, Carter, A.2,
Sun, C.-L.2, Forman, S.2, Bhatia, S.2 1Departments of Pediatrics and
Medicine, University of Minnesota, Minneapolis, MN; 2City of Hope
National Medical Center, Duarte, CA.
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